Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer

Table 1 Patient characteristics in upper rectum and middle/lower rectum groups

Characteristics	Total		Upper		Middle/Lower		P-value
	N	(%)	n = 58	(%)	n = 115	(%)
Age, median, year (range)	61(34–93)		63.5(34–87)		61(34–93)		0.268
Age
< 65	109	63	35	60.3	74	64.3	0.607
> = 65	64	37	23	39.7	41	35.7
Gender
Male	115	66.5	33	56.9	82	71.3	0.063
Female	58	33.5	25	43.1	33	28.7
Clinical tumor depth
T2	11	6.4	3	5.2	8	7	0.108
T3	137	79.2	41	70.7	96	83.5
T4a	13	7.5	10	17.2	3	2.6
T4b	12	6.9	4	6.9	8	7
Clinical lymph node metastasis
N0	28	16.2	7	12.1	21	18.3	0.611
N1	106	61.3	40	69	66	57.4
N2a	28	16.2	10	17.2	18	15.7
N2b	11	6.4	1	1.7	10	8.7
Clinical stage
2	28	16.2	7	12.1	21	18.3	0.297
3	145	83.8	51	87.9	94	81.3
Pretreatment CEA (ng/ml)
< = 5	110	63.6	35	60.3	75	65.2	0.53
> 5	63	36.4	23	39.7	40	34.8
Concurrent chemotherapy
Fluoropyrimidine	94	54.3	29	50	65	56.5	0.416
FOLFOX	79	45.7	29	50	50	43.5
RT technique
3DCRT^a	44	25.4	15	25.9	29	25.2	0.927
IG-IMRT^b	129	74.6	43	74.1	86	74.8
Median RT dose, Gy (range)
5000 (4500–5400)			5000 (4500–5040)		5000 (4500–5400)		0.454
Adjuvant chemotherapy
Yes	122	70.5	44	75.9	78	67.8	0.274
No	51	29.5	14	24.1	37	32.2
Median follow-up, month (range)
	35(6–73)		32(7–71)		36(6–73)		0.992

^athree-dimensional conventional radiotherapy; ^bimage guided intensity modulated radiotherapy

ISSN: 1748-717X